Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

Anker, SD; Butler, J; Filippatos, G; Khan, MS; Ferreira, JP; Bocchi, E; Bohm, M; Brunner-La Rocca, HP; Choi, DJ; Chopra, V; Chuquiure, E; Giannetti, N; Gomez-Mesa, JE; Janssens, S; Januzzi, JL; Gonzalez-Juanatey, JR; Merkely, B; Nicholls, SJ; Perrone, SV; Pina, IL; Ponikowski, P; Senni, M; Seronde, MF; Sim, D; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Vinereanu, D; Zhang, J; Jamal, W; Schnaidt, S; Schnee, JM; Brueckmann, M; Pocock, SJ; Zannad, F; Packer, M

Anker, SD (corresponding author), Charite Univ Med Berlin, Dept Cardiol CVK, Augustenburger Pl 1, D-13353 Berlin, Germany.

EUROPEAN JOURNAL OF HEART FAILURE, 2020; 22 (12): 2383

Abstract

Aims EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFp......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索